Main Page

From SCAN

Jump to: navigation, search

Sweden Cancerome Analysis Network - Breast

Swedishflagthumb.png
På svenska


A Network among surgeons, pathologists, oncologists, radiologists, nurses, and biologists who strive to improve survival and quality of life for breast cancer patients through the

SCAN-B Logo
  • Introduction of gene expression and genomic tumor profiling into the clinical routine for breast cancer
  • Improved methods for tumor classification, diagnosis, prognostication and prediction of treatment effects
  • Eventual implementation in health care, clinical trials, cooperation with drug and biotech industry, and an accelerated pipeline towards personalized care
The SCAN-B Initiative was launched in 2010 as a multicenter collaboration between hospitals in Malmö, Lund, Helsingborg, Växjö, Halmstad, Kristianstad and Karlskrona in the southern health care region of Sweden (ClinicalTrials.gov identifier NCT02306096). In October 2013 the northern region Uppsala joined SCAN-B. The long-term goals of the project are to develop new diagnostic, prognostic, and treatment-predictive clinical tests for breast cancer. These novel clinical tools can then be implemented in the care of future breast cancer patients to allow for a more refined, individualized, and optimized medical decision-making process. We will accomplish these goals by using the latest advanced genomic technologies (housed at the Canceromics Branch, Division of Oncology and Pathology, Lund University) to study the molecular profiles of breast tumor samples from patients on a prospective basis (~1500 patients/year).

All patients with primary breast cancer are eligible and may be enrolled in the study following informed consent. Patients in the study receive the exact same treatment as patients who are not in the study. Participation means that a blood sample is drawn prior to surgery; then following surgical removal of the cancer, a small piece of the patient's tumor is sent for genomic analysis (if there is tissue available after the standard clinical diagnostics and pathology review). Patients in the study will also be requested to provide simple blood draws at regular intervals during their treatment. Participation in the study is a valuable gift towards future breast cancer patients because we believe that only through the analysis of thousands of molecular profiles of individual patient tumors will we be able to develop the most effective and beneficial clinical tests to improve patient survival and quality of life. All information is confidential and protected by patients' rights. The study has been approved by the regional ethical, biobanking and data inspection review boards.

As of March 2015, over 6500 patients with breast cancer have elected to be a part of SCAN-B. We thank all participants for their contributions to this important initiative. In the first phase, we have commenced whole-transcriptome gene expression profiling using next-generation deep-sequencing of tumor RNA (RNA-seq).

The SCAN-B Initiative is supported by the South Swedish Breast Cancer Group, the Swedish Regional Cancer Center South, and is performed in collaboration with participating surgeons, pathologists, radiologists, oncologists, clinical chemists, nurses, biomedical assistants and cancer researchers of the Division of Oncology and Pathology, SCIBLU Genomics and CREATE Health Centre.

The project was initiated by Professor Åke Borg and is lead by the SCAN-B Steering Committee. The SCAN-B project is made possible by generous funding provided by the Berta Kamprad Foundation.


SCAN-B Publications


SCAN-B Steering Committee

Åke Borg, Ph.D.
Professor and Head, Canceromics Branch, Familial Breast Cancer Unit
Division of Oncology and Pathology, Clinical Sciences, Lund
Dorthe Grabau, M.D., Ph.D.
Clinical Pathologist, Department of Pathology
Skåne's University Hospital, Lund
Cecilia Hegardt, Ph.D.
Assistant Professor and Head, Cancer Stem Cells Unit
Division of Oncology and Pathology, Clinical Sciences, Lund
Christer Larsson, Ph.D.
Professor, Molecular Pathology
Division of Translational Cancer Research, Department of Laboratory Medicine, Lund
Niklas Loman, M.D., Ph.D.
Clinical Oncologist, Division of Oncology
Skåne's University Hospital, Lund
Martin Malmberg, M.D., Ph.D. (committee chairperson)
Clinical Oncologist, Division of Oncology
Skåne's University Hospital, Lund
Jonas Manjer, M.D., Ph.D.
Surgeon, Department of Surgery
Skåne's University Hospital, Malmö
Lisa Rydén, M.D., Ph.D.
Surgeon and Chair, South Swedish Breast Cancer Group
Department of Surgery, Skåne's University Hospital, Lund
Lao Saal, M.D., Ph.D.
Assistant Professor and Head, Translational Oncogenomics Unit
Division of Oncology and Pathology, Clinical Sciences, Lund


Views
Personal tools
Navigation